Abdulsalam Al Kassab, MD
Endocrinology, Diabetes & Metabolism · Rochester Hills, MINPI 1477560308
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $296,440 of the $350,709 with a category attached, or 84.5%. 60 manufacturers reported payments, led by Novo Nordisk at 36.6% of the total. Reporting peaked in 2019 at $85,789 and has fallen 63.0% since, to $31,723 in 2025. Among endocrinology, diabetes & metabolism clinicians in MI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 943 payments — averaging $371.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$128K
- Abbott$32K
- Sanofi-aventis U.S. LLC$29K
- Boehringer Ingelheim$29K
- Corcept Therapeutics$28K
- Merck$25K
- plus $80K from 54 others
What the payments were for
- Consulting fees$19,2305%
- Speaking & faculty fees$296,44085%
- Travel & lodging$16,4145%
- Food & beverage$18,5875%
- Education$380%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- RYBELSUS$49,054
- JARDIANCE$48,548
- Ozempic$48,481
- Korlym$26,533
- STEGLATRO$24,005
- TOUJEO$15,469
- Kerendia$15,252
- FARXIGA$14,009
- SOLIQUA 100/33$13,573
- Tresiba$11,657
- FREESTYLE LIBRE 3$11,462
- FreeStyle Libre Pro$7,675
- FreeStyle Libre 2$7,360
- Synthroid$5,827
- FreeStyle Libre$4,500
- V-GO$2,400
- Xultophy 100/3.6$2,335
- TEPEZZA$1,400
- MYCAPSSA$1,227
- ZEGALOGUE$400
How this compares
$350,709 in reported general payments places this provider in the 95th percentile of 219 endocrinology, diabetes & metabolism providers in Michigan.
See all endocrinology, diabetes & metabolism providers in Michigan →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 688 | $1,245,523 |
| JardianceEmpagliflozin | 856 | $1,162,570 |
| KorlymMifepristone | 28 | $1,123,243 |
| MounjaroTirzepatide | 339 | $502,170 |
| FarxigaDapagliflozin Propanediol | 351 | $412,095 |
| TrulicityDulaglutide | 213 | $377,075 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 230 | $333,356 |
| Novolog FlexpenInsulin Aspart | 558 | $244,479 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 189 | $215,081 |
| JanuviaSitagliptin Phosphate | 147 | $208,505 |
| Humalog Kwikpen U-100Insulin Lispro | 374 | $195,023 |
| Tresiba Flextouch U-100Insulin Degludec | 169 | $143,951 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 587 | $135,332 |
| RybelsusSemaglutide | 37 | $93,889 |
| Humalog Kwikpen U-200Insulin Lispro | 28 | $88,199 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Novolog | $128,190 | $1,378,832832 claims |
| Boehringer IngelheimJardiance, Tradjenta, Synjardy Xr | $28,910 | $1,239,459917 claims |
| Corcept TherapeuticsKorlym | $27,705 | $1,123,24328 claims |
| Lilly USA, LLCMounjaro, Trulicity | $21,444 | $879,246552 claims |
| AstraZenecaFarxiga | $14,360 | $412,095351 claims |
| MerckJanuvia, Janumet, Janumet Xr | $24,672 | $272,213190 claims |
| BayerKerendia | $17,807 | $83,68847 claims |
| PfizerGenotropin | $122 | $76,56827 claims |
| Radius Health, Inc.Tymlos | $253 | $73,24519 claims |
| AbbVieSynthroid | $6,146 | $68,385612 claims |
| AmgenProlia | $2,031 | $49,28129 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $28,950 | $31,78531 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 219 endocrinology, diabetes & metabolism providers in Michigan.
Other endocrinology, diabetes & metabolism in Rochester Hills
- Farah Dawood FarahRochester Hills$14K
- Smita BijlaniRochester Hills$9K
- Marwah HusseinRochester Hills$8K
- Lima LawrenceRochester Hills$8K
- Lowell SchmeltzFarmington Hills$1.3M
- George GrunbergerBloomfield Hills$931K
- Gary EdelsonFarmington Hills$503K
- Michael BrennanSaint Clair Shores$433K
- Jamal HammoudFlint$386K
- Richard AuchusAnn Arbor$250K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.